Peter Forsberg MD

140 posts

Peter Forsberg MD

Peter Forsberg MD

@ForsbergMD

Oncologist at @ColoradoBlood | Myeloma, Amyloid, WM, BMT, CAR-T | Opinions are my own

Katılım Ağustos 2017
209 Takip Edilen331 Takipçiler
Peter Forsberg MD retweetledi
DAVA Oncology
DAVA Oncology@DAVAOnc·
Peter Forsberg, MD @ForsbergMD @ColoradoBlood reviews the expanding elranatamab program: MagnetisMM-6 shows 97% ORR with Elra+Dara+Len in TI-NDMM, plus novel combos with iberdomide (MM-30) & upcoming FASTER and ElLen trials in TE-NDMM. #DAVAWhistler
DAVA Oncology tweet mediaDAVA Oncology tweet mediaDAVA Oncology tweet mediaDAVA Oncology tweet media
English
0
4
6
429
Peter Forsberg MD retweetledi
Ankit kansagra
Ankit kansagra@kansagraMD·
New data in Blood Advances on managing post-cilta-cel lymphocyte expansion (Forsberg et al, Colorado Blood Cancer Institute, n=53). Peak ALC >5000/µL was associated with atypical neurologic events (OR 6.8, p=.016) and significantly worse OS (HR 6.2, p=.011). Median OS in the high-ALC group without intervention: 104 days. With dex prophylaxis or ALC ≤5000: not reached (p=.0013). Caveat: retrospective cohort comparison
Ankit kansagra tweet media
English
1
1
4
742
Jeff Sharman
Jeff Sharman@jeff_sharman·
Proud of the team!
Peter Forsberg MD@ForsbergMD

Our data from @ColoradoBlood is out now. We developed an approach using dex for excessive lymphocyte expansion after Cilta-Cel. Instituted along with more stringent bridging we subsequently observed improvements in non-relapse mortality and reduced severe atypical neurotox events

English
1
0
2
609
Peter Forsberg MD retweetledi
Robert Z. Orlowski
Robert Z. Orlowski@Myeloma_Doc·
#Myeloma Paper of the Day: Dexamethasone prophylaxis for high lymphocyte expansion (ALC >5000/μL, which predicted severe early neurologic events/high mortality) post-cilta-cel in myeloma demonstrates promise for risk mitigation, including better OS: pubmed.ncbi.nlm.nih.gov/41894686/. #mmsm
Robert Z. Orlowski tweet mediaRobert Z. Orlowski tweet mediaRobert Z. Orlowski tweet mediaRobert Z. Orlowski tweet media
English
4
13
35
6K
Peter Forsberg MD
Peter Forsberg MD@ForsbergMD·
We’ve since reduced of ALC cutoff to 3k. Our approach didn’t prevent cranial nerve palsies & impact on IEC-EC is unclear. Dex is likely not the perfect tool for T cell modulation but it’s a real work applicable strategy to try to move the needle on cilta-cel safety in clinic now.
English
0
0
4
193
Peter Forsberg MD
Peter Forsberg MD@ForsbergMD·
Our data from @ColoradoBlood is out now. We developed an approach using dex for excessive lymphocyte expansion after Cilta-Cel. Instituted along with more stringent bridging we subsequently observed improvements in non-relapse mortality and reduced severe atypical neurotox events
Robert Z. Orlowski@Myeloma_Doc

#Myeloma Paper of the Day: Dexamethasone prophylaxis for high lymphocyte expansion (ALC >5000/μL, which predicted severe early neurologic events/high mortality) post-cilta-cel in myeloma demonstrates promise for risk mitigation, including better OS: pubmed.ncbi.nlm.nih.gov/41894686/. #mmsm

English
2
3
29
4.1K
Peter Forsberg MD retweetledi
Luciano J Costa
Luciano J Costa@End_myeloma·
The 2025 IMS/IMWG high-risk definition was built on cohorts of patients treated prior to introduction of QUADS. We showed that the new criteria outperform legacy definitions in a cohort of 310 patients treated with QUAD +ASCT @SusanBal9 @bhemato @DholariaMD
CoMMit-Myeloma Trial Innovated@CoMMitTrials

***COMMIT Publication Alert*** British Journal of Haematology | Wiley Online Library onlinelibrary.wiley.com/doi/10.1111/bj…

English
1
13
36
6.4K
Peter Forsberg MD retweetledi
Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽
Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽@Rfonsi1·
It is time to change the nomenclature for MM treatment regimen acronyms. If it involves a Bispecific or CART, we need to add -Ig at the end to recognize the need for: - Proactive - Sufficient - Ongoing until needed - Closely monitored IgG replacement. Saying that an "x% of patients were replaced" is not enough. When? To what level? etc. It should never go under 400 mg/dL, and probably higher. We need to account for the M-spike concentration in IgG MM. With CART and bispecifics we are using regardless. #ASH25RF #mmsm
English
3
9
45
7.6K
Peter Forsberg MD retweetledi
Binaytara
Binaytara@binaytara·
@ForsbergMD settles the triplet vs quad wars at #HemeSummit25: The winner is resoundingly the four-drug combinations! 5 RCTs in TE, 3 in TIE all meeting primary endpoints. Adding CD38 MoAb to PI+IMiD+Dex induction has reshaped NDMM expectations with improved disease control & minimal added toxicity. Time to dive into the weeds! #TripletVsQuad #NDMM @HCAhealthcare @SarahCannonDocs #ALL #CLLsm #hemepath #lymsm #leusm #CART #MedEd #MedX #MedTwitter
Binaytara tweet mediaBinaytara tweet media
English
0
1
4
119
Peter Forsberg MD
Peter Forsberg MD@ForsbergMD·
Really looking forward to this IMF event! Excited to be part of a great lineup of speakers, should be a fantastic opportunity for patients in the region.
International Myeloma Foundation@IMFmyeloma

#Denver #myeloma community, we want to see you at our RCW on 6/21! At this free IMF event, you'll learn about diagnosis, maintenance therapy, relapse information, clinical trial update, & more, all from multiple myeloma experts. RSVP today: mmsm.link/4koSV9E

English
5
0
2
204
Peter Forsberg MD retweetledi
Luciano J Costa
Luciano J Costa@End_myeloma·
Colorado @ColoradoBlood; Alabama @ONealCancerUAB; NY @Columbia @rajshekharucms; Tennesse @ Vanderbilt @DholariaMD ; Wisconsin @MedicalCollege @bhemato and Madison @nsc_natalie; Washington @fredhutch @RahulBanerjeeMD @DimaDanai ; Oregon @OHSUKnight R. Silberman and E. Medvedova.
Luciano J Costa@End_myeloma

Newly diagnosed with MM? MASTER-2 addressed response adapted therapy with the perspective of finite treatment. Accruing fast! #mmsm

Italiano
2
8
18
3.9K
Peter Forsberg MD retweetledi
Rahul Banerjee, MD, FACP
Rahul Banerjee, MD, FACP@RahulBanerjeeMD·
#DAVAWhistler @MileHighMyeloma noting how quickly the field of Waldenstrom’s is advancing with new tools… I remember when ibrutinib + venetoclax was new… now one study is moving onto zanu + sonrotoclax!
Rahul Banerjee, MD, FACP tweet media
English
0
7
21
2.1K

Keşfet

@ColoradoBlood @MileHighMyeloma @LNastoupilMD @jeff_sharman @JoshuaRichterMD @SurbhiSidanaMD @Myeloma_Society @SusanBal9